Kornimate/medical-research-clean huggingface dataset:
nf2 natural history consortium

Conditions: Schwannoma, Vestibular; Neurofibromatosis 2; Meningioma

Summary: objectives: i. define the growth rates and clinical course of nf2-related tumors in patients with neurofibromatosis type 2. associate growth rate with physical function.

protocol outline: data on the clinical course and growth rate of nf2-related tumors in patients with neurofibromatosis 2. patients are evaluated each year on a cranial and a spinal mri, eye tests, hearing tests, quality of life, neurological tests, and physical functioning.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosed with neurofibromatosis 2 on or after 01/01/93 * must meet one of the following conditions: bilateral vestibular schwannoma or family history of neurofibromatosis 2 (first degree family relative) and unilateral vestibular schwannoma at under 30 years or any 2 of the following: meningioma glioma schwannoma juvenile posterior subcapsular lenticular opacity/juvenile cortical cataract * no plans to treat vestibular schwannoma in next 12 months --prior/concurrent therapy-- * not specified --patient characteristics-- * age: 5 and over
evidence of spreading vasoconstriction in human gingiva

Conditions: Vasoconstriction; Oral Soft Tissue Conditions; Dental and Gingival Conditions

Summary: the aim of this study is to observe the mechanism of spreading vasoconstriction in human healthy gingiva. epinephrine solution is applied on the attached gingiva in group "a" and on the surface of the tooth next to the ginvial sulcus in group "b". the different placement of the solution causes different effect in the microcirculation.

spatial regulation of gingival microcirculation has not been revealed yet. although this could be an important mechanism to protect gingiva as it is exposed to mechanical, chemical, thermal etc. irritation during whole life. it is especially important during flap surgery. laser speckle contrast imaging (lsci) is novel non-invasive method with high spatio-temporal resolution, therefore it allows us to study remote effect of local vasoconstriction such as spreading vasoconstriction in human gingiva. the epinephrine is a daily used vasoconstrictor material in dentistry and it will be used to trigger remote effect on gingiva. epinephrine in 1 mg/ml concentration. solution will be dropped on the gingiva at tooth 12 in a fabricated leakage proof well attached to 2mm above the marginal gingiva in group "a". the solution will be dropped on the surface of tooth 12 next to the sulcus into the well in case of group "b". the changes of the blood flow will be monitor at the test side with surrounding gingival area by lsci. the control side in each case will be - appropriately to the test side - at tooth 21 with phisiologocal saline.

Eligibility criteria:
inclusion criteria: * at least 5 mm keratinized gingiva at the upper front teeth * general health exclusion criteria: * pregnancy, breast-feeding * any medication * smoking, gingivitis, caries and coronal restoration with insufficient marginal integrity

Keywords: spreading vasoconstriction gingival microcirculation
nitrite effects on cardiac muscle in cabg

Conditions: Coronary Artery Disease; Atherosclerosis; Vascular Diseases; Cardiac Disease; Diabetes Mellitus

Summary: the purpose of this study is to test whether sodium nitrite affects the expression of cellular proteins important for metabolic and vascular function in vascular offcuts and cardiac biopsies taken from patients undergoing coronary artery bypass grafting (cabg) surgery.

nitrite has been shown in recent studies to improve cardiac performance, particularly in patients with heart failure. these improvements were demonstrated in measures that are independent of cardiac loading conditions, implying improved contractility via effects at a cellular level. in humans, coronary artery bypass graft (cabg) surgery presents an opportunity to safely obtain cardiac muscle biopsies and vascular tissue in order to investigate changes at a cellular level in these tissues. the aim of this study is to investigate whether sodium nitrite affects the expression of cellular proteins important for heart muscle metabolism and vascular function when infused prior to routine cabg surgery. patients undergoing cabg surgery who provide written informed consent will receive intravenous sodium nitrite 24hours prior to surgery, 30 minutes prior to surgery, or placebo. as type 2 diabetes mellitus is common in patients undergoing cabg surgery, and itself has profound effects on metabolism, these patients will be sub-grouped into a diabetic cohort for interpretation of the molecular biology results. the 24hours prior to surgery vs. placebo arm will take place first, followed by the 30minutes prior to surgery vs. placebo arm. the data from this study will provide important information on the effects of nitrite on heart muscle and blood vessel tissues, and inform larger clinical trials in patients with cardiovascular disease.

Eligibility criteria:
inclusion criteria: males or females aged \>18years scheduled to undergo coronary artery bypass grafting. exclusion criteria: inability to read and understand the consent form and patient information leaflet pregnancy and any woman of child bearing potential patients with type i diabetes significant medical, surgical or psychiatric disease that in the opinion of the patient's attending physician would affect subject safety and participation in the trial including severe heart failure (nyhaiii-iv and ef\<40%) and severe renal impairment (requiring dialysis). unstable coronary syndrome (within 2 weeks) known glucose-6-phosphate dehydrogenase (g6pd) deficiency or g6pd deficiency measured at screening in males of african, asian or mediterranean decent. receipt of an investigational drug or biological agent within the 4 weeks prior to study entry or 5 times the drug half-life, whichever is the longer. intended heart valve surgery or additional surgery or redo-cabg surgery.
vertebral artery origin treatment via endovascular techniques registry (voter)

Conditions: Vertebral Artery Stenosis

Summary: a retrospective and prospective registry of patients admitted for stroke and evidence of vertebral artery origin stenosis (vaos).

a retrospective registry of stenting plus medical management for the prevention of recurrent stroke in patients with symptomatic vertebral artery origin stenosis (vaos). this study is collecting information on clinical outcomes up to 18 months post-treatment. on january 6, 2025, voter was changed from prospective to retrospective.

Eligibility criteria:
inclusion criteria: 1. patients between 18 and 90 years of age 2. patient has experienced a posterior circulation ischemic event 3. patient has angiographically confirmed bilateral vertebral artery origin disease (hypoplasia, occlusion, or stenosis). 4. patient has \>50% stenosis on the side being targeted for therapy exclusion criteria: 1. pregnant women 2. contrast indication to the use of anti-platelet drugs 3. there is tandem vertebral or basilar artery stenosis 4. the serum creatinin is \>2.5 5. baseline modified rankin score is \>3 6. \< 5 years life expectancy
sahoor meal regimen for patients with type1 diabetes

Conditions: Type1diabetes; Fasting Hypoglycemia

Summary: to examine effects of two approaches to sahoor meal consumption during ramadan on blood sugar control and incidence of early day hypoglycemic episodes requring the discontinuation of fasting.

most studies and guidelines regarding insulin dose adjustments have focused on basal insulin modification rather than boluses or timing of meals. there hasn't been so far any study that examines a specific dose reduction or timing that is best to avoid early day (post suhoor) hypo or hyperglycemia, and the advised dose reductions are based on expert opinion with small observational studies that used certain dose changes. the timing of sleep and meals are different during ramadan and therefore have a direct impact on blood glucose levels, we demonstrated in a previous prospective cohort of 156 t1dm patients contrary to other studies, the post suhoor and early day period had the highest incidence time for hypoglycemia in the saudi population. it is therefore necessary to understand how adjustments to the timing of the meals and their doses can achieve better glycemic control during fastin ramadan. current guidelines recomend that the suhoor meal is delayed as much as possible in order to reduce the fasting duration to be taken with a claculated insulin dose. however, the concern is that this would not allow patients to correct the hypoglycemic or hyperglycemic events related to miscalculation of suhoor insulin dose if they occur as the fasting time begins and they must break their fast to correct their blood glucose levels. many people with t1dm do not count meal carbohydrates correctly, therefore, there is a need for an approach that allows patients to correct their blood glucose levels after having a large meal that requires insulin administration without having to break their fast, as well as the ability to have a snack or a late suhoor without the need for insulin administration to minimize the fasting period and insure that the blood glucose is in range before starting to fast. the approach that we are proposing will allow patients to do that by having the suhoor meal with its bolus at least two hours before fasting begins, and having a low carbohydrate snack - late suhoor- just before starting to fast without the need for insulin administration (regimen 1). it is going to be compared with having the suhoor with its insulin bolus just before the start of fasting (regimen 2).

Eligibility criteria:
inclusion criteria: 1. dm type 1 2. age \> 14 years 3. diagnosis of type 1 dm of more than 6 months. 4. committed to do smbg or on cgm 5. on multiple daily injections or insulin pumps 6. on carbohydrate counting for meal dosing 7. have previously fasted ramadan 8. are willing to fast this year 9. well educated about requirements for fasting ramadan exclusion criteria: 1. cognitive impairment or learning disability 2. renal and hepatic impairment 3. adrenal insufficiency 4. pregnancy 5. alcohol consumption 6. any diagnosed psychiatric disease
pilot study: echocardiographic and hemodynamic effects of esmolol in septic shock patients

Conditions: Shock, Septic

Summary: after initial hemodynamic stabilization, 36 septic shock patients with heart rate \> of 90 bpm and requiring norepinephrine to maintain mean arterial pressure (map) more than 65 mmhg will be randomised into two groups, esmolol group and control group. patients allocated to esmolol group will receive a continuous esmolol infusion to maintain a lowering of heart rate of 10%. norepinephrine will be titrated to achieve a map more than 65 mmhg. to investigate myocardial performance, the investigators will assess tissue doppler imaging by echocardiography and hemodynamic measures. data will be obtained at baseline ,after esmolol infusion once achieved the predefined heart rate threshold and 72hours after esmolol infusion.

primary outcome were determined according to our previous study of tissue doppler.

Eligibility criteria:
inclusion criteria: * septic shock * fluid optimization * with a cardiac index \> 3 l/min/m2 * heart rate \>90 /min exclusion criteria: * cardiogenic shock * bradycardia * history of severe asthma * indications against esmolol

Keywords: esmolol hypotension shock, septic sepsis systemic inflammatory response syndrome adrenergic beta-1 receptor antagonists adrenergic antagonists pharmacologic actions physiological effects of drugs
the medication experience study

Conditions: Hypertension; Elevated Cholesterol; Diabetes; Depression

Summary: the purpose of this study is to evaluate whether participation in an internet-based intervention helps improve medication use.


Eligibility criteria:
inclusion criteria: * any male or female 18 years or older, filling prescriptions for oral medications for hypertension, high cholesterol, diabetes, or depression at the downtown health plaza, piedmont plaza, or cancer center pharmacies. exclusion criteria: * inability to complete internet surveys due to inadequate internet access, not understanding a survey written in english, or lack of computer skills. * patient does not intend to continue using the same wfbmc-affiliated pharmacy for the next 12 months.

Keywords: prescriptions hypertension high cholesterol diabetes depression adherence
effectiveness of the propeller health (formerly asthmapolis) monitoring system

Conditions: Asthma

Summary: propeller health is collaborating with dignity health (formerly catholic healthcare west (chw)) to carry out a focused demonstration project to evaluate the effectiveness and potential cost savings of a deployment of the propeller health approach to asthma management. the propeller health goal is to bring together the best technology and asthma insight in order to provide dignity health with an engaging, data-driven chronic care program to improve asthma management and lower healthcare utilization costs, and to respond to prevention-focused reforms to health insurance laws. this project has been designed to implement and evaluate a data-driven program to improve asthma management and control and lower direct costs through reductions in healthcare utilization. this program has been developed by propeller health and has gone through preliminary testing. each subject participating in the study will receive an propeller health device, which captures the time and location of use of inhaled short-acting bronchodilators over a twelve-month period. this information is processed and delivered at regular intervals to the patient and his or her provider to support improved asthma management.

the purpose of the study is to evaluate the impact of the adoption of the propeller health system into a healthcare organization, and to provide sufficient information to inform decision making for potential future adopters. the researchers believe that the propeller health system has the potential to improve asthma control by providing rescue inhaler actuation data and tailored asthma management tips to patients with uncontrolled asthma, and rescue inhaler actuation data to their providers. improvements in asthma control should be reflected in reductions in healthcare utilization for asthma, and potentially for general healthcare utilization. reductions in utilization would result in lower healthcare costs. the study has been designed to capture data on individual subject asthma control, and changes in utilization and costs over a one-year introduction period.

Eligibility criteria:
inclusion criteria: * provider diagnosis of asthma (icd9 493.xx); * at least one healthcare utilization event in chw within last 12 months; and * prescription for short acting beta agonist (saba) at study intake. exclusion criteria: * subject is under the age of 5 at the beginning of the study; * subject does not speak either english or spanish; * subject does not have access to the internet or email to receive reports; and * subject has substantial co-morbidity (provider diagnosis of copd

Keywords: asthma healthcare utilization costs
long-term cardiovascular risk in cured cushing's patients

Conditions: Cushing's Disease

Summary: the purpose of this study is to determine whether subjects who have been affected by cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.


Eligibility criteria:
inclusion criteria: * patients who have been cured of cushing's disease at least 5 years ago. exclusion criteria: * patients who have been cured of cushing's disease more than 15 years ago.

Keywords: cushing's disease
a study to evaluate the efficacy and safety of autogene cevumeran with nivolumab versus nivolumab alone in participants with high-risk muscle-invasive urothelial carcinoma (miuc)

Conditions: Muscle Invasive Urothelial Carcinoma

Summary: the main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk miuc. in this study participants will be enrolled in a safety run-in phase to receive autogene cevumeran + nivolumab. this phase will be conducted to monitor and ensure the safety of study participants. after all participants in the safety run-in have been enrolled to receive autogene cevumeran + nivolumab, further participants will be randomization in either autogene cevumeran + nivolumab or the saline + nivolumab arm.


Eligibility criteria:
inclusion criteria: * histologically confirmed muscle-invasive uc (also termed tcc) of the bladder or upper urinary tract * tnm classification (uicc/ajcc 7th edition) at pathological examination of surgical resection specimen of (y)pt3-4 or (y)pn+ and m0 * surgical resection of miuc of the bladder or upper tract * participants who have not received prior neoadjuvant cisplatin chemotherapy (nac) must be ineligible to receive adjuvant cisplatin therapy due to patient refusal, cisplatin ineligibility or investigator decision * tumor tissue must be provided for biomarker analysis * absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (ct) or magnetic resonance imaging (mri) scan of the pelvis, abdomen, and chest no more than 28 days prior to randomization. * full recovery from cystectomy or nephroureterectomy within 120 days following surgery * eastern cooperative oncology group (ecog) performance status of 0 or 1 * negative hiv test at screening * no evidence of active hepatitis b, defined as having a negative hepatitis b surface antigen (hbsag) test at screening * negative hepatitis c virus (hcv) antibody test at screening, or a positive hcv antibody test followed by a negative hcv rna test at screening exclusion criteria: * partial cystectomy in the setting of bladder cancer primary tumor or partial nephroureterectomy in the setting of renal pelvis primary tumor * any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment * any prior neoadjuvant immunotherapy * adjuvant chemotherapy or radiation therapy for uc following surgical resection * malignancies other than uc within 5 years prior to randomization * treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
can mcpn intervention improve injection site rotation

Conditions: Injection Site Rotation; Diabete Mellitus

Summary: the current research study has accordingly been designed to determine if a "pharmacist-dispensed montméd coloured pen needle (mcpn) intervention" will improve injection site rotation relative to the standard dispensing of non-mcpn insulin pen needles.

study design and conduct this is a 30-day, two-arm, randomized, controlled study. enrolled participants will be randomly assigned to one of the following study arms: * control group: participating pharmacists will dispense boxes of standard insulin pen needles to the patient participants * mcpn group: participating pharmacists will dispense boxes of montméd coloured pen needles to the patient participants study sites and participating pharmacists all pharmacies in canada that provide services to individuals with diabetes who use injectable insulin therapy will be eligible to participate in this study. all participating pharmacists who will play an active role in participant enrollment and the follow-up visits will be required to complete a participation consent form and 2 surveys. the first (pre-study survey) should be completed after they have been fully trained on the study protocol and their study obligations, and before commencement of study enrollment. the second (post-study survey) should be completed after the last patient has completed the 30-day follow-up visit. (refer to section 11 for the study flow). randomization process participating pharmacists will dispense one of the two study pen needles according to a computer-generated list that will be provided to the participating pharmacy upon site activation

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus or type 2 diabetes mellitus who have been using daily insulin therapy for 1 year or more * able to read the english text on the boxes of the pen needles exclusion criteria: * individuals currently treated with a glucagon-like peptide 1 receptor agonist (glp-1ra) * current or previous user of mcpn * individuals who are unable to understand or communicate in english * pregnant women * individuals with serious mental illnesses eg. dementia, schizophrenia disorders, bipolar disorders, major depression, etc.
desflurane-induced myocardial protection

Conditions: Aortic Valve Stenosis

Summary: this study examines pharmacological preconditioning and post conditioning of desflurane by comparing cardiac troponin release in patients receiving either desflurane or propofol for the aortic valve surgery.

patients scheduled for aortic valve replacement with use of cardiopulmonary bypass are included in the study. patients are assigned to desflurane group (des) or propofol group (prop). des receives desflurane (1-2 mac) inhalation between the induction of anesthesia and cardiopulmonary bypass (cpb). after the induction of cpb, the anesthesia in des is switched to a total intravenous anesthesia (tiva) with propofol. prop receives a tiva during the surgery. all patients receive a continuous infusion of remifentanil. biomarker of myocardial damage troponin i is examined at 4 points; t1: after the induction of anesthesia, t2: arrival at icu, t3: 12 hours after the icu arrival, t4: 24 hours after the icu arrival, t5: third post operative day (3pod).

Eligibility criteria:
inclusion criteria: * patients scheduled for aortic valve replacement with use of cardiopulmonary bypass. exclusion criteria: * patients younger than 20 years old. * recent myocardial infarction (within 1 year). * renal dysfunction (gfr less than 50ml/min). * known allergy to study drugs including propofol.

Keywords: aortic valve replacement
a study of saquinavir soft gel capsules (sgc) used in combination with two other anti-hiv drugs in patients with hiv-associated kidney disease

Conditions: HIV Infections; AIDS-Associated Nephropathy

Summary: the purpose of this study is to compare the safety and effectiveness of saquinavir sgc plus stavudine (d4t) plus lamivudine (3tc) with that of saquinavir sgc plus nelfinavir plus d4t in patients with hiv-associated kidney disease. this study examines whether these drug combinations are effective in preventing kidney disease from progressing to a stage where it is immediately life threatening. this study also examines the effect these drug combinations have on the level of hiv detected in these patients. finally, this study evaluates the drug level (the amount of drug found in the body) of these two combinations in patients with kidney disease.

this is an open-label, non-comparative, randomized, single center, 24-week study. patients are stratified into 3 groups (8 patients in each group) based on kidney function: group 1: serum creatine less than 2 mg/dl. group 2: serum creatine 2-5 mg/dl. group 3: serum creatine greater than 5 mg/dl. all 24 patients are randomized 1:1 to receive 1 of 2 study regimens: arm a: saquinavir sgc plus d4t plus 3tc. arm b: saquinavir sgc plus nelfinavir plus d4t. patients are seen at weeks 4, 8, 12, and 24. at week 24, a kidney biopsy is performed with patient consent.

Eligibility criteria:
inclusion criteria patients must have: * detectable hiv-1 rna by amplicor assay. * biopsy-proven nephropathy. exclusion criteria prior medication: excluded: * saquinavir and nelfinavir. * d4t or 3tc within the past 4 months. required: stable antiretroviral therapy for more than 4 weeks.

Keywords: kidney failure, chronic hiv-1 drug therapy, combination stavudine hiv protease inhibitors lamivudine saquinavir aids-associated nephropathy reverse transcriptase inhibitors viral load nelfinavir